The United Kingdom and the United States have agreed to a major trade agreement that will keep zero import taxes on British medicine products being sold in the US market.
Agreement Details of the Deal
As part of the deal, the UK has committed to raise funding on medicines through the NHS. This move secures that tariffs on these key goods will be held at nothing for a period of the next three years.
This development is in response to recent statements to dramatically increase tariffs on branded drug products, with increases mentioned up to one hundred percent.
"This agreement with the UK strengthens the international landscape for new treatments and introduces long-overdue balance to transatlantic medicine commerce," a statement declared.
Commercial Significance
Drugs represent one of the the United Kingdom's largest goods shipped to the United States, which is by far the largest market for leading UK drugmakers.
Statistics reveal that in the one-year period to the end of last September, the UK sold medicines totaling over eleven billion pounds to the US. This figure accounted for a significant portion of all goods exports in that timeframe.
"This agreement secures employment, increases investment and sets the stage for the UK to become a international leader for biotech and pharma," a government official commented.
Specific NHS Changes
The pact includes several key changes from the United Kingdom:
- Higher Cost Ceiling: The UK will increase the affordability limit at which it considers new medicines to be too expensive by a quarter.
- Higher Drug Budget: There is a goal to raise total health service expenditure on treatments from 0.3 percent of the national economy to 0.6 percent over the coming ten years.
- Rebate Cap: The percentage manufacturers must pay back to the NHS to control costs will be limited at fifteen percent. Previously, refunds exceeded 20%.
Broader Context
The deal follows a long-running tension between the drug companies and the British authorities over spending levels and NHS adoption.
These tensions were heightened by assertions that US consumers were paying a premium for the identical medicines than consumers in the Britain and the EU.
Recently, several large drug company projects in the UK have been delayed or cancelled, while multi-billion-dollar funding commitments have been announced toward US facilities.
The Science Minister stated that the NHS needed to invest a greater share on treatments, noting that its budget allocation on drugs had declined as a percentage of its resources over the past decade.
